United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - ibuprofen - oral tablet - 400mg

Singapore - English - HSA (Health Sciences Authority)

luye pharma (singapore) pte. ltd. - quetiapine fumarate 460.50mg eqv quetiapine - tablet, extended release - 400 mg - quetiapine fumarate 460.50mg eqv quetiapine 400 mg

Singapore - English - HSA (Health Sciences Authority)

viatris private limited - gabapentin - capsule - 400 mg - gabapentin 400 mg

Singapore - English - HSA (Health Sciences Authority)

boehringer ingelheim singapore pte. ltd. - nevirapine anhydrous - tablet, extended release - 400 mg - nevirapine anhydrous 400 mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

rivopharm (uk) ltd - gabapentin - oral capsule - 400mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

mawdsley-brooks & company ltd - ibuprofen - oral tablet - 400mg

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - celecoxib 400mg;   - capsule - 400 mg - active: celecoxib 400mg   excipient: croscarmellose sodium gelatin lactose monohydrate magnesium stearate povidone sodium laurilsulfate tekprint green sb-4027 titanium dioxide - symptomatic treatment of pain and inflammation in osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. for the management of acute pain and treatment of primary dysmenorrhoea in adults. the decision to prescribe a selective cox-2 inhibitor should only be made: · if non-pharmacological interventions and simple analgesic therapies have been tried and found to lack analgesic efficacy or to have unacceptable adverse effects in the individual patient, and · after assessment of the individual patient's overall risks. as the cardiovascular risks of the selective cox-2 inhibitors may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used. patients on long-term treatment should be reviewed regularly, such as every three months, with regards to efficacy, risk factors and ongoing need for treatment.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

kenso corporation (m) sdn. bhd. - carfentrazone-ethyl; liquid hydrocarbon - emulsifiable concentrate - carfentrazone-ethyl ungrouped active 400.0 g/l; liquid hydrocarbon solvent other 531.0 g/l - herbicide

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - selexipag, quantity: 1400 microgram - tablet, film coated - excipient ingredients: mannitol; maize starch; hyprolose; hypromellose; propylene glycol; magnesium stearate; titanium dioxide; carnauba wax; iron oxide yellow - uptravi is indicated for the treatment of:,- idiopathic pulmonary arterial hypertension;,- heritable pulmonary arterial hypertension;,- pulmonary arterial hypertension associated with connective tissue disease;,-pulmonary arterial hypertension associated with congenital heart disease with repaired shunts;,-pulmonary arterial hypertension associated with drugs and toxins;,in patients with who functional class ii, iii or iv symptoms

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

noumed life sciences ltd - gabapentin - oral capsule - 400mg